{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:30:06Z","timestamp":1787689806949,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anemia and iron deficiency are common in heart failure (HF) and chronic kidney disease (CKD). These conditions are associated with upregulation of hepcidin, which impairs the enteric absorption of iron, limiting the use of oral iron formulations in these populations. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are associated with enhanced erythropoiesis and have been shown to augment the erythropoietic response to intravenous iron. The effect of baseline SGLT2i therapy in the erythropoietic response following oral iron supplementation is currently not known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the erythropoietic response to oral iron supplementation in patients with HF or CKD, using and not using SGLT2i as background therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a retrospective analysis of ambulatory patients with HF or CKD followed in cardio-kidney-metabolic clinics from a quaternary care hospital in Canada and a tertiary care hospital from Portugal. An age- and sex-matched population of patients using (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200976) and not using (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200976) a SGLT2i was compared for changes in hemoglobin and hematocrit following oral iron supplementation. Secondary outcomes included changes in iron biomarkers, natriuretic peptides and kidney function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, the mean age was 75\u2009\u00b1\u20099\u00a0years, 49% were men, 119 (78%) had CKD, 107 (70%) HF, and 113 (74%) had anemia. After adjustment for baseline differences, SGLT2i users experienced a greater increase in hemoglobin and hematocrit compared to SGLT2i non-users: hemoglobin\u2009+\u20090.80\u00a0g\/dL (95% confidence interval [CI] 0.39\u20131.21\u00a0g\/dL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001); hematocrit\u2009+\u20093.0% (95% CI 1.0\u20134.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). No significant differences on iron biomarkers or any of the secondary outcomes were found between the groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Oral iron supplementation in patients with background therapy including a SGLT2i (vs. SGLT2i non-users) was associated with a greater increase in hemoglobin and hematocrit. These results suggest that patients with HF or CKD patients treated with SGLT2i might have an enhanced erythropoietic response to oral iron supplementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-025-02685-6","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:33:47Z","timestamp":1748345627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Erythropoietic response to oral iron with sodium-glucose co-transporter 2 inhibitors"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-5461","authenticated-orcid":false,"given":"Pedro","family":"Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Matias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoforos K.","family":"Travlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"Ang\u00e9lico-Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Diniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Vasques-N\u00f3voa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Fri\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Tsoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Mavrakanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2685_CR1","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/ejhf.1818","volume":"22","author":"MS Khan","year":"2020","unstructured":"Khan MS, Samman Tahhan A, Vaduganathan M et al (2020) Trends in prevalence of comorbidities in heart failure clinical trials. Eur J Heart Fail 22:1032\u20131042","journal-title":"Eur J Heart Fail"},{"key":"2685_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/01.CIR.0000134279.79571.73","volume":"110","author":"I Anand","year":"2004","unstructured":"Anand I, McMurray JJ, Whitmore J et al (2004) Anemia and its relationship to clinical outcome in heart failure. Circulation 110:149\u2013154","journal-title":"Circulation"},{"key":"2685_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.semnephrol.2006.05.006","volume":"26","author":"DS Silverberg","year":"2006","unstructured":"Silverberg DS, Wexler D, Iaina A, Schwartz D (2006) The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 26:296\u2013306","journal-title":"Semin Nephrol"},{"key":"2685_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.23354","volume":"88","author":"DB Bregman","year":"2013","unstructured":"Bregman DB, Morris D, Koch TA, He A, Goodnough LT (2013) Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 88:97\u2013101","journal-title":"Am J Hematol"},{"key":"2685_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31\u201339","journal-title":"Lancet"},{"key":"2685_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL et al (2022) SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400:757\u2013767","journal-title":"Lancet"},{"key":"2685_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJ et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7:845\u2013854","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2685_CR8","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","volume":"43","author":"F Zannad","year":"2022","unstructured":"Zannad F, Ferreira JP, Butler J et al (2022) Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. Eur Heart J 43:4991\u20135002","journal-title":"Eur Heart J"},{"key":"2685_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D et al (2018) How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41:356\u2013363","journal-title":"Diabetes Care"},{"key":"2685_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000531084","volume":"55","author":"M Packer","year":"2024","unstructured":"Packer M (2024) Mechanistic and clinical comparison of the erythropoietic effects of SGLT2 inhibitors and prolyl hydroxylase inhibitors in patients with chronic kidney disease and renal anemia. Am J Nephrol 55:255\u2013259","journal-title":"Am J Nephrol"},{"key":"2685_CR11","first-page":"106","volume":"11","author":"M Packer","year":"2023","unstructured":"Packer M (2023) Potential interactions when prescribing SGLT2 inhibitors and intravenous iron in combination in heart failure. Heart Fail 11:106\u2013114","journal-title":"Heart Fail"},{"key":"2685_CR12","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1210\/clinem\/dgaa057","volume":"105","author":"H Ghanim","year":"2020","unstructured":"Ghanim H, Abuaysheh S, Hejna J et al (2020) Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab 105:e1056\u2013e1063","journal-title":"J Clin Endocrinol Metab"},{"key":"2685_CR13","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","volume":"146","author":"KF Docherty","year":"2022","unstructured":"Docherty KF, Welsh P, Verma S et al (2022) Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation 146:980\u2013994","journal-title":"Circulation"},{"key":"2685_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ejhf.2735","volume":"25","author":"C Fuchs Andersen","year":"2023","unstructured":"Fuchs Andersen C, Omar M, Glenth\u00f8j A et al (2023) Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial. Eur J Heart Fail 25:226\u2013234","journal-title":"Eur J Heart Fail"},{"key":"2685_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ejhf.2992","volume":"25","author":"P Marques","year":"2023","unstructured":"Marques P, Matias P, Packer M et al (2023) Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium\u2013glucose cotransporter 2 inhibitors. Eur J Heart Fail 25:2191\u20132198","journal-title":"Eur J Heart Fail"},{"key":"2685_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15691","author":"P Marques","year":"2024","unstructured":"Marques P, Mavrakanas TA, Guida J et al (2024) Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: proof-of-concept results from the DECIDE-CV clinical programme. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/dom.15691","journal-title":"Diabetes Obes Metab"},{"key":"2685_CR17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/ejhf.2409","volume":"24","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Anker SD, Butler J et al (2022) Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-reduced. Eur J Heart Fail 24:708\u2013715. https:\/\/doi.org\/10.1002\/ejhf.2409","journal-title":"Eur J Heart Fail"},{"key":"2685_CR18","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC, Bock AH, Carrera F et al (2014) FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 29:2075\u20132084","journal-title":"Nephrol Dial Transplant"},{"key":"2685_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"key":"2685_CR20","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S (2019) Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139:1985\u20131987","journal-title":"Circulation"},{"key":"2685_CR21","doi-asserted-by":"crossref","unstructured":"Vasques-N\u00f3voa F, Pimentel MJ, Marques P et al (2024) Ferritin, inflammation, and iron deficiency in acute heart failure: evidence from the EDIFICA cohort. Clin Res Cardiol 1\u20138","DOI":"10.1007\/s00392-024-02535-x"},{"key":"2685_CR22","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","volume":"44","author":"M Packer","year":"2023","unstructured":"Packer M (2023) Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium\u2013glucose cotransporter 2 inhibitors. Eur Heart J 44:5027\u20135035","journal-title":"Eur Heart J"},{"key":"2685_CR23","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/ejhf.2286","volume":"23","author":"WG Herrington","year":"2021","unstructured":"Herrington WG, Savarese G, Haynes R et al (2021) Cardiac, renal, and metabolic effects of sodium\u2013glucose co-transporter 2 inhibitors: a position paper from the European society of cardiology ad-hoc task force on sodium\u2013glucose co-transporter 2 inhibitors. Eur J Heart Fail 23:1260\u20131275","journal-title":"Eur J Heart Fail"},{"key":"2685_CR24","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/ejhf.2731","volume":"24","author":"M Packer","year":"2022","unstructured":"Packer M (2022) How can sodium\u2013glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-deficient? Implications for understanding iron homeostasis in heart failure. Eur J Heart Fail 24:2287\u20132296","journal-title":"Eur J Heart Fail"},{"key":"2685_CR25","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.jacc.2024.07.013","volume":"84","author":"M Packer","year":"2024","unstructured":"Packer M, Ferreira JP, Butler J et al (2024) Reaffirmation of mechanistic proteomic signatures accompanying SGLT2 inhibition in patients with heart failure: a validation cohort of the EMPEROR program. J Am Coll Cardiol 84:1979\u20131994","journal-title":"J Am Coll Cardiol"},{"key":"2685_CR26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12933-023-01904-6","volume":"22","author":"M Benedikt","year":"2023","unstructured":"Benedikt M, Mangge H, Aziz F et al (2023) Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction\u2013a post-hoc analysis of the EMMY trial. Cardiovasc Diabetol 22:166","journal-title":"Cardiovasc Diabetol"},{"key":"2685_CR27","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1001\/jama.2017.5427","volume":"317","author":"GD Lewis","year":"2017","unstructured":"Lewis GD, Malhotra R, Hernandez AF et al (2017) Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 317:1958\u20131966","journal-title":"JAMA"},{"key":"2685_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2459\/JCM.0000000000000736","volume":"20","author":"AP Ambrosy","year":"2019","unstructured":"Ambrosy AP, Lewis GD, Malhotra R et al (2019) Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. J Cardiovasc Med 20:223\u2013225","journal-title":"J Cardiovasc Med"},{"key":"2685_CR29","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/ndt\/gfv293","volume":"31","author":"PA Kalra","year":"2016","unstructured":"Kalra PA, Bhandari S, Saxena S et al (2016) A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 31:646\u2013655","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02685-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02685-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02685-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:33:49Z","timestamp":1748345629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02685-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":29,"alternative-id":["2685"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02685-6","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PM received salary support from an educational grant by Janssen. MP reports consulting fees from 89Bio, Abbvie, Altimmune, Amgen, Ardelyx, AstraZeneca, Boehringer-Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Lilly, Moderna, Novartis, Reata, Regeneron, Relypsa and Salamandra. MAT reports personal fees from Boehringer-Ingelheim, AstraZeneca, Janssen, Novo-Nordisk and Eli Lilly, outside the submitted work. TAM received speaker honoraria from Daiichi Sankyo, BMS Canada, Janssen, Astra Zeneca, and Pfizer and has served on advisory boards for B\u00f6hringer Ingelheim, Bayer, GSK, and Servier outside the submitted work. He has also received an unrestricted research grant from Astra Zeneca and operational grants from the Kidney Foundation of Canada, the Heart & Stroke foundation of Canada and the Canadian Institute of Health Research. He is receiving salary support from the Fonds de Recherche Quebec Sant\u00e9 (Junior 1 Clinician Scholar Award # 298742) and is supported by a KRESCENT New Investigator Award. AS has received support from the Fonds de Recherche Sant\u00e9 Quebec (FRSQ) Junior 1 clinician scholars\u2019 program, Canadian Institute of Health Research (Grant #175095), Roche Diagnostics, Boehringer-Ingelheim, Novartis, Janssen, Novo-Nordisk, Servier, AstraZeneca, and Takeda. JPF has received research support from Boehringer-Ingelheim, AstraZeneca and Novartis, through his institution, the University of Porto. The reminder authors report not having relevant conflicts of interest regarding the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}